NOSU
NOTICE OF SUIT
04/15/2026
Back to search
Official data from USPTO
ANTARES PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ANTARES PHARMA
ST13
US500000078147508Class
42
Filing
78147508
Registration
3150417
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
45
Latest update
04/16/2026
Trademark type
Word
Nice classes
42
Filing date
07/25/2002
Registration date
10/03/2006
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/07/2016
Last transaction
04/16/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
01/31/2001
First use in commerce
03/15/2001
Drawing code
1
Owner type
03
Owner location
Ewing, NJ, US
Examiner
BOAGNI, MARY
Law office
M50
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Antares Pharma, Inc.
Antares Pharma, Inc.
Representatives
Gene K. Park Morgan, Lewis & Bockius LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Medical research in drug delivery systemstransdermal drugs and transdermal drug delivery systems; pharmaceutical products design and development for others
Publications
History of USPTO decisions and trademark events.
45 publications found
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/03/2025
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
12/07/2016
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
12/07/2016
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
12/07/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
12/07/2016
E89R
TEAS SECTION 8 & 9 RECEIVED
09/28/2016
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
10/03/2015
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
05/30/2012
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
05/30/2012
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/30/2012
ES8R
TEAS SECTION 8 RECEIVED
05/10/2012
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/16/2008
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/16/2008
EXPT
EXPARTE APPEAL TERMINATED
10/03/2006
R.PR
REGISTERED-PRINCIPAL REGISTER
10/03/2006
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/08/2006
PUBO
PUBLISHED FOR OPPOSITION
07/11/2006
NPUB
NOTICE OF PUBLICATION
06/21/2006
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/23/2006
ALIE
ASSIGNED TO LIE
05/05/2006
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/29/2006
XAEC
EXAMINER'S AMENDMENT ENTERED
04/26/2006
GNEA
EXAMINERS AMENDMENT E-MAILED
04/26/2006
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/26/2006
ATRV
ATTORNEY REVIEW COMPLETED
04/25/2006
PGTT
PETITION GRANTED - TTAB APPEAL FILED
04/05/2006
PETR
PETITION TO REVIVE-RECEIVED
03/16/2006
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/16/2006
PROA
TEAS PETITION TO REVIVE RECEIVED
03/16/2006
EXPT
EXPARTE APPEAL TERMINATED
03/16/2006
EXPI
EX PARTE APPEAL-INSTITUTED
03/16/2006
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
03/16/2006
MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
03/06/2006
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
03/04/2006
GNFR
FINAL REFUSAL E-MAILED
08/06/2005
CNFR
FINAL REFUSAL WRITTEN
08/06/2005
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
07/15/2005
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
11/29/2004
GNSL
LETTER OF SUSPENSION E-MAILED
09/15/2003
CFIT
CASE FILE IN TICRS
07/21/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/07/2003
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/07/2003
GNRT
NON-FINAL ACTION E-MAILED
01/09/2003
DOCK
ASSIGNED TO EXAMINER
12/10/2002
Continuous trademark protection
Get notified about every new filing that threatens ANTARES PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.